Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer

Several anaplastic lymphoma kinase inhibitors (ALKIs) have demonstrated excellent efficacy on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and also better adverse effect (AE) profiles compared to cytotoxic chemotherapy in advanced stage anaplastic lymphoma k...

Full description

Bibliographic Details
Main Authors:	Cheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, Yu-Chen Tsai, Kuan-Li Wu, I-Hua Chen, Kung-Chao Chen, Jui-Ying Lee, Yong-Chieh Chang, Chin-Ling Chen, Yu-Kang Tu, Jen-Yu Hung, Chih-Jen Yang, Inn-Wen Chong
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	Cancers
Subjects:	network meta-analysis crizotinib alectinib ceritinib brigatinib ensartinib
Online Access:	https://www.mdpi.com/2072-6694/13/8/1966

Similar Items

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
by: Jain RK, et al.
Published: (2017-10-01)

From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
by: Lee AT, et al.
Published: (2023-06-01)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
by: Qian Zhu, et al.
Published: (2017-06-01)

Drug interactions between ALK inhibitors and warfarin with concurrent use of bucolome: a case report
by: Takashi Kato, et al.
Published: (2023-05-01)

Role and targeting of anaplastic lymphoma kinase in cancer
by: Carminia Maria Della Corte, et al.
Published: (2018-02-01)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
by: Deng L, et al.
Published: (2018-09-01)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
by: Tung Hoang, et al.
Published: (2020-02-01)

Current approaches to therapy of ALK-positive non-small cell lung cancer
by: К. К. Laktionov, et al.
Published: (2021-06-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
by: Ken Koshikawa, et al.
Published: (2020-06-01)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016-05-01)

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
by: Sara Verdura, et al.
Published: (2022-12-01)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
by: Valerio Gristina, et al.
Published: (2020-12-01)

Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor
by: Roberto Ravasio, et al.
Published: (2022-10-01)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
by: Gianluca Spitaleri, et al.
Published: (2023-05-01)

Targeted therapy of brain metastases in patients with ALK-positive non-small cell lung cancer: A review
by: Dina D. Sakaeva, et al.
Published: (2021-12-01)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)

Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report
by: Henan BAI, et al.
Published: (2021-08-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
by: Zihua Zou, et al.
Published: (2022-01-01)

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
by: Cesare Gridelli, et al.
Published: (2023-11-01)

Focus on Alectinib and Competitor Compounds for Second Line Therapy in ALK Rearranged NSCLC
by: Samuel J Klempner, et al.
Published: (2016-11-01)

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib
by: Yuki Matsumura, et al.
Published: (2021-08-01)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
by: Chuangzhou Rao, et al.
Published: (2022-09-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
by: S. G. Bagrova, et al.
Published: (2019-12-01)

Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
by: Peng Gao, et al.
Published: (2022-02-01)

ALK‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
by: Lianxi Song, et al.
Published: (2022-04-01)

Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells
by: Tina Jost, et al.
Published: (2022-05-01)

ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
by: Kai Ou, et al.
Published: (2021-09-01)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
by: Mezquita L, et al.
Published: (2018-01-01)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
by: Ryohei Katayama, et al.
Published: (2016-01-01)

Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2020-04-01)

A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report
by: Hong Yang, et al.
Published: (2022-10-01)

Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report
by: Flávia Amaral Duarte, et al.
Published: (2021-01-01)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
by: Xing Huang
Published: (2018-02-01)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
by: Kunyan Sun, et al.
Published: (2021-06-01)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
by: Scott N. Gettinger, MD, et al.
Published: (2022-09-01)

First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis
by: Kuan-Li Wu, et al.
Published: (2021-09-01)

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
by: Zhifeng Ye, et al.
Published: (2023-03-01)

Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases
by: Qing Zhang, PhD, et al.
Published: (2023-04-01)